HLS Therapeutics Inc experiences a mixed week in the market as it navigates through its financial landscape and stock performance.
HLS Therapeutics Inc (HLS.TO) has seen a week of modest gains, closing at C$4.20 on Friday. This reflects a slight decline of 1.18% for the day but an overall increase of 2.19% over the week. The company continues to attract attention from analysts and investors due to its recent financial results and product developments.
Investor takeaway: Investors should consider HLS Therapeutics' recent financial performance and product launches while keeping an eye on its stock movements against its historical averages and analyst outlooks.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$132.92M
52W high
$5.76
52W low
$4.00
1W change
+2.19%
Beta
0.86
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 73.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.28
+73.3% Upside
Current Price
C$4.20
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
29.8%
Annualized
90-Day Vol
22.5%
Annualized
Trend (90d)
-48.1%
Annualized drift
90d Mean
C$3.54
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.97 | C$3.58 – C$4.40 |
| 60 trading days | C$3.75 | C$3.24 – C$4.33 |
| 90 trading days | C$3.54 | C$2.96 – C$4.23 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
C$4.20 close with YTD decline of 13.40%
HLS Therapeutics' stock has experienced a year-to-date decline of 13.40%, indicating ongoing challenges despite recent revenue growth.
Bull case
The launch of NILEMDO™ and the growth in Vascepa sales could signal potential revenue growth, which may encourage a positive outlook among investors.
Bear case
Despite recent gains, HLS Therapeutics has a negative profit margin and declining year-to-date performance, which may raise concerns for risk-averse investors.
Weekly Price Action
Advertisement
This week, HLS Therapeutics Inc stock closed at C$4.20, reflecting a decline of 1.18% on Friday. However, the stock has gained 2.19% over the week, indicating some resilience in the face of market fluctuations. Year-to-date, the stock has decreased by 13.40%, highlighting ongoing challenges.
Company News and Web Headlines
No significant company news was reported this week. However, recent headlines include financial results from the first quarter of 2026, where HLS reported a revenue increase of 2% year-over-year, reaching $12.9 million. Additionally, the company noted a 15% growth in Vascepa net sales and the launch of NILEMDO™ in April 2026, which may contribute positively to future earnings.
Technical Picture
From a technical perspective, HLS Therapeutics is currently trading below its 50-day moving average of C$4.34 and its 200-day moving average of C$4.66, indicating a bearish trend. The stock has a 52-week trading range of C$4.00 to C$5.76, with its current price being approximately 11% of that range. The stock's beta is 0.86, suggesting lower volatility compared to the market. Volume for the day was 12,652 shares, which is 1.45 times the 20-day average volume of 8,713 shares, indicating increased trading activity.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
